Yin-xiang Wang

发表

A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?

Xing Wang, Shi Yan, Shaolei Li, 2015, Clinical lung cancer.

The Abl-related gene (Arg) requires its F-actin–microtubule cross-linking activity to regulate lamellipodial dynamics during fibroblast adhesion

A. Koleske, M. Mooseker, Ann L. Miller, 2004, The Journal of cell biology.

Therapeutic effects and adverse drug reactions are affected by icotinib exposure and CYP2C19 and EGFR genotypes in Chinese non-small cell lung cancer patients.

Dongyang Liu, Ji Jiang, P. Hu, 2014, Asian Pacific journal of cancer prevention : APJCP.

Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies.

Wei He, Xiao-dong Zhang, Yin-xiang Wang, 2012, Lung cancer.

The Abl-related gene (Arg) nonreceptor tyrosine kinase uses two F-actin-binding domains to bundle F-actin

A. Koleske, M. Mooseker, Ann L. Miller, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.

Ying Cheng, C. Bai, Yi-long Wu, 2013, The Lancet. Oncology.

Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer.

Yuankai Shi, Yan Sun, Yin-xiang Wang, 2015, Future oncology.

The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study

Dong Wang, Yuankai Shi, S. Qin, 2015, PloS one.

A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).

B. Han, Yiping Zhang, Shucai Zhang, 2014, Lung cancer.

Icotinib versus gefi tinib in previously treated advanced non-small-cell lung cancer ( ICOGEN ) : a randomised , double-blind phase 3 non-inferiority trial

C. Bai, Yuankai Shi, S. Qin, 2013 .

Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors.

Xinshan Kang, Dongmei Zhang, Shaojing Hu, 2012, Bioorganic & medicinal chemistry letters.

Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study.

Yiping Zhang, Shucai Zhang, K. Ying, 2013 .

Cloning of tumor-associated differentially expressed gene-14, a novel serine protease overexpressed by ovarian carcinoma.

K. Shigemasa, T. Parmley, T. O'brien, 1999, Cancer research.

A Phase I Study of the Safety and Pharmacokinetics of Higher-Dose Icotinib in Patients With Advanced Non-Small Cell Lung Cancer

Jian Liu, Xingjiang Hu, Jun-chun Chen, 2016, The oncologist.

Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer.

Ji Jiang, P. Hu, Fen-lai Tan, 2011, Chinese medical journal.